Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, et al. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol. 2019;37:97–104.

Article  CAS  PubMed  Google Scholar 

Shen J, Liu G, Qi H, Xiang X, Shao J. JMJD5 inhibits lung cancer progression by facilitating EGFR proteasomal degradation. Cell Death Dis. 2023;14:657.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Passaro A, Jänne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2:377–91.

Article  CAS  PubMed  Google Scholar 

Pan Z, Wang K, Wang X, Jia Z, Yang Y, Duan Y, et al. Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression. Mol Cancer. 2022;21:77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alam SK, Zhang Y, Wang L, Zhu Z, Hernandez CE, Zhou Y, et al. DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma. Oncogene. 2022;41:83–98.

Article  CAS  PubMed  Google Scholar 

Song H, Liu D, Wang L, Liu K, Chen C, Wang L, et al. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma. Mol Cancer. 2022;21:43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu L, Ke L, Zhang Z, Yu J, Meng X. Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. Front Oncol. 2020;10:602762.

Article  PubMed  PubMed Central  Google Scholar 

Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12:31–46.

Article  CAS  PubMed  Google Scholar 

Nagaraju GP, Farran B, Luong T, El-Rayes BF. Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistance: A brief overview. Semin Cancer Biol. 2023;88:67–80.

Article  CAS  PubMed  Google Scholar 

Zheng Y, Wang L, Yin L, Yao Z, Tong R, Xue J, et al. Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and Therapies. Front Oncol. 2022;12:873994.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heng WS, Gosens R, Kruyt F. Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting. Biochem Pharm. 2019;160:121–33.

Article  CAS  PubMed  Google Scholar 

He Y, Jiang X, Duan L, Xiong Q, Yuan Y, Liu P, et al. LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway. Mol Cancer. 2021;20:156.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sneha S, Nagare RP, Sidhanth C, Krishnapriya S, Garg M, Ramachandran B, et al. The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary. Cell Oncol (Dordr). 2020;43:601–16.

Article  CAS  PubMed  Google Scholar 

Li H, Feng Z, He ML. Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells. Theranostics. 2020;10:7053–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin ML, Jeong KW. Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective. Exp Mol Med. 2023;55:1333–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yi Y, Li P, Huang Y, Chen D, Fan S, Wang J, et al. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer. Oncogene. 2022;41:4318–29.

Article  CAS  PubMed  Google Scholar 

Yan R, Fan X, Xiao Z, Liu H, Huang X, Liu J, et al. Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness. Cancer Lett. 2022;531:83–97.

Article  CAS  PubMed  Google Scholar 

Jia Z, Zhang Y, Yan A, Wang M, Han Q, Wang K, et al. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells. Cell Death Dis. 2020;11:670.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jia Z, Wang K, Duan Y, Hu K, Zhang Y, Wang M, et al. Claudin1 decrease induced by 1,25-dihydroxy-vitamin D3 potentiates gefitinib resistance therapy through inhibiting AKT activation-mediated cancer stem-like properties in NSCLC cells. Cell Death Discov. 2022;8:122.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lei HM, Zhang KR, Wang CH, Wang Y, Zhuang GL, Lu LM, et al. Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. Theranostics. 2019;9:7122–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, et al. Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Nat Commun. 2018;9:3198.

Article  PubMed  PubMed Central  Google Scholar 

Liu Z, Yan W, Liu S, Liu Z, Xu P, Fang W. Regulatory network and targeted interventions for CCDC family in tumor pathogenesis. Cancer Lett. 2023;565:216225.

Article  CAS  PubMed  Google Scholar 

Wang J, Zhang YW, Zhang NJ, Yin S, Ruan DJ, He N, et al. Coiled-Coil Domain Containing 80 Suppresses Nonylphenol-Induced Colorectal Cancer Cell Proliferation by Inhibiting the Activation of ERK1/2. Front Cell Dev Biol. 2021;9:759820.

Article  PubMed  PubMed Central  Google Scholar 

Hong WF, Zhu DX, Chen YJ, Shen XZ, Cui YH, Du SS, et al. Coiled-coil domain-containing 154 promotes colorectal cancer proliferation and metastasis via interacting with minichromosome maintenance complex component 2. Cancer Lett. 2023;578:216460.

Article  CAS  PubMed  Google Scholar 

Qi W, Shao F, Huang Q. Expression of Coiled-Coil Domain Containing 34 (CCDC34) and its Prognostic Significance in Pancreatic Adenocarcinoma. Med Sci Monit. 2017;23:6012–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geng W, Liang W, Fan Y, Ye Z, Zhang L. Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion. Mol Med Rep. 2018;17:465–73.

CAS  PubMed  Google Scholar 

Liu LB, Huang J, Zhong JP, Ye GL, Xue L, Zhou MH, et al. High Expression of CCDC34 Is Associated with Poor Survival in Cervical Cancer Patients. Med Sci Monit. 2018;24:8383–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gong Y, Qiu W, Ning X, Yang X, Liu L, Wang Z, et al. CCDC34 is up-regulated in bladder cancer and regulates bladder cancer cell proliferation, apoptosis and migration. Oncotarget. 2015;6:25856–67.

Article  PubMed  PubMed Central